thalidomide has been researched along with Aging in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "As Thalidomide survivors reach their mid-50's they are experiencing a wide range of secondary health problems, in particular musculoskeletal problems, and depression and anxiety, with multimorbidity a growing issue." | 3.91 | The health and quality of life of Thalidomide survivors as they age - Evidence from a UK survey. ( Atkin, K; Glendinning, C; Newbronner, E; Wadman, R, 2019) |
| "Between 1957 and 1962 thalidomide was used as a nonaddictive, nonbarbiturate sedative that also was successful in relieving the symptoms of morning sickness in early pregnancy." | 3.85 | "The legacy of thalidomide" - A multidisciplinary meeting held at the University of York, United Kingdom, on September 30, 2016. ( Atkin, K; Newbronner, E; Vargesson, N, 2017) |
| "The drug caused severe birth defects." | 2.58 | The changing health of Thalidomide survivors as they age: A scoping review. ( Atkin, K; Newbronner, E, 2018) |
| "Thalidomide (5-50mg/kg) was intraperitoneally administered immediately after laparotomy." | 1.46 | Thalidomide alleviates postoperative pain and spatial memory deficit in aged rats. ( Guo, P; Hu, SP, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beyer, R | 1 |
| Peters, KM | 1 |
| Schulte-Hillen, J | 1 |
| Stück, V | 1 |
| Niecke, A | 1 |
| Newbronner, E | 3 |
| Vargesson, N | 1 |
| Atkin, K | 3 |
| Guo, P | 1 |
| Hu, SP | 1 |
| Hwang, YY | 1 |
| Au-Yeung, R | 1 |
| Lau, HP | 1 |
| Kwong, YL | 1 |
| Glendinning, C | 1 |
| Wadman, R | 1 |
| Musto, P | 1 |
| Simeon, V | 1 |
| Grossi, A | 1 |
| Gay, F | 1 |
| Bringhen, S | 1 |
| Larocca, A | 1 |
| Guariglia, R | 1 |
| Pietrantuono, G | 1 |
| Villani, O | 1 |
| D'Arena, G | 1 |
| Cuomo, C | 1 |
| Musto, C | 1 |
| Morabito, F | 1 |
| Petrucci, MT | 1 |
| Offidani, M | 1 |
| Zamagni, E | 1 |
| Tacchetti, P | 1 |
| Conticello, C | 1 |
| Milone, G | 1 |
| Palumbo, A | 1 |
| Cavo, M | 1 |
| Boccadoro, M | 1 |
| Fan, QY | 1 |
| Ramakrishna, S | 1 |
| Marchi, N | 1 |
| Fazio, V | 1 |
| Hallene, K | 1 |
| Janigro, D | 1 |
| Huang, MC | 1 |
| Greig, NH | 1 |
| Luo, W | 1 |
| Tweedie, D | 1 |
| Schwartz, JB | 1 |
| Longo, DL | 1 |
| Ferrucci, L | 1 |
| Ershler, WB | 1 |
| Goetzl, EJ | 1 |
| Schröder, JM | 1 |
| Gibbels, E | 1 |
2 reviews available for thalidomide and Aging
| Article | Year |
|---|---|
[National Competence Network Contergan - Ensuring medical care for people with thalidomide embryopathy].
Topics: Aging; Female; Fetal Diseases; Humans; Patient Care; Psychophysiologic Disorders; Thalidomide | 2022 |
The changing health of Thalidomide survivors as they age: A scoping review.
Topics: Aging; Comorbidity; Congenital Abnormalities; Disabled Persons; Female; Health Status; Humans; Menta | 2018 |
8 other studies available for thalidomide and Aging
| Article | Year |
|---|---|
"The legacy of thalidomide" - A multidisciplinary meeting held at the University of York, United Kingdom, on September 30, 2016.
Topics: Abnormalities, Drug-Induced; Adult; Aging; Child; Disabled Persons; Female; Humans; Hypnotics and Se | 2017 |
Thalidomide alleviates postoperative pain and spatial memory deficit in aged rats.
Topics: Acute Pain; Aging; Animals; Cytokines; Inflammation Mediators; Locomotion; Male; Memory Disorders; P | 2017 |
Complete response of age-related Epstein-Barr virus-associated polymorphic nodal lymphoproliferative disease of plasmacytic type to low-dose lenalidomide.
Topics: Aged, 80 and over; Aging; Antigens, CD; Epstein-Barr Virus Infections; Humans; Immunocompromised Hos | 2018 |
The health and quality of life of Thalidomide survivors as they age - Evidence from a UK survey.
Topics: Adult; Aging; Anxiety; Depression; Employment; Female; Humans; Hypnotics and Sedatives; Male; Middle | 2019 |
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Ital
Topics: Aged; Aging; Antigens, CD34; Biomarkers; Cell Count; Cell Separation; Cyclophosphamide; Female; Gran | 2015 |
Combined effects of prenatal inhibition of vasculogenesis and neurogenesis on rat brain development.
Topics: Aging; Animals; Animals, Newborn; Blood Vessels; Blood-Brain Barrier; Brain; Brain Chemistry; Brain | 2008 |
Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide.
Topics: Adult; Aged; Aging; bcl-X Protein; Cell Proliferation; Cell Survival; Cells, Cultured; Chemokine CCL | 2011 |
[Unmyelinated nerve fibers in senile nerves and in late thalidomide neuropathy: a quantitative electron microscopic study (author's transl)].
Topics: Aged; Aging; Axons; Biopsy; Female; Humans; Male; Microscopy, Electron; Middle Aged; Nerve Degenerat | 1977 |